- Apprendre à connaître
les acteurs clés du
cycle vicieux de l’ostéolyse métastatique. 
-
L’incidence et les répercussions des métastases osseuses et des complications osseuses
Les douleurs osseuses constituent la complication la plus courante de la maladie osseuse métastatique1
Les douleurs osseuses représentent le type le plus courant de douleurs associées au cancer et ont été jugées graves et débilitantes chez deux tiers des patients13. Le traitement des douleurs osseuses demeure, par conséquent, un facteur de la prise en charge de la maladie osseuse métastatique14.
Références:
- Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(Suppl 8):1588-1594.
- Rubens RD, Coleman RE. Bone metastases. Dans : Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Clinical Oncology. New York, NY: Churchill Livingstone; 1995:643-665.
- Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243-6249.
- Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. Cancer J Clin 2008;58:71-96.
- Papagelopoulos PJ, Savvidou OD, Galanis EC et al. Advances and challenges in diagnosis and management of skeletal metastases. Orthopedics 2006;29(7):609-622.
- Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
- Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Instit 2004;96:879-882.
- Rosen LS, Gordon D, Tchekmedyian NS et al. Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003:21:3150-3157.
- Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-1090.
- Berenson JR, Lichtenstein A, Porter L et al. on behalf of the Myeloma Aredia Study Group. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593-602.
- Kanis JA, Johnell O, De Laet C et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-382.
- Domcheck SM, Younger J, Finkelstein DM et al. Predictors of Skeletal Complications in Patients with Metastatic Breast Carcinoma. Cancer 2000;89:363-368.
- Gralow J and Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage 2007;33:462-472.
- Janjan N. Bone metastases: approaches to management. Semin Oncol 2001;28(11):28-34.
Ce site est destiné uniquement aux professionnels de la santé canadiens.
